Retracted: Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways

Liu Li; Lu Huizhi; Wang Binu; Deng Xinxin; Wu Longjun; Yang Liping; Zhang Yingying

doi:10.12659/MSM.937840

Retracted: Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways

Med Sci Monit. 2022 Jul 19:28:e937840. doi: 10.12659/MSM.937840.

Authors

Liu Li¹, Lu Huizhi², Wang Binu¹, Deng Xinxin¹, Wu Longjun¹, Yang Liping¹, Zhang Yingying¹

Affiliations

¹ Department of Ear, Nose and Throat (ENT), Tongren Hospital of WuHan University (Wuhan Third Hospital), Wuhan, Hubei, China (mainland).
² Department of Critical Care Medicine, Tongren Hospital of WuHan University (Wuhan Third Hospital), Wuhan, Hubei, China (mainland).

Abstract

An editorial decision has been made to retract this manuscript due to breach of publishing guidelines, following the identification of non-original and manipulated figures. Reference: Liu Li, Lu Huizhi, Wang Binu, Deng Xinxin, Wu Longjun, Yang Liping, Zhang Yingying. Anticancer Activity of Mukonal Against Human Laryngeal Cancer Cells Involves Apoptosis, Cell Cycle Arrest, and Inhibition of PI3K/AKT and MEK/ERK Signalling Pathways. Med Sci Monit, 2018; 24: 7295-7302. DOI: 10.12659/MSM.910702.

Publication types

Retraction of Publication